Global and China trends and forecasts of disease burden for female lung Cancer from 1990 to 2021: a study based on the global burden of disease 2021 database

Abstract Background In recent years, due to various risk factors, the incidence, prevalence, and mortality rates of female lung cancer have been increasing in both China and globally. This has become a significant public health challenge worldwide. Lung cancer not only poses a severe threat to women...

Full description

Saved in:
Bibliographic Details
Main Authors: Bilu Li, Yuyan Wu, Yanhong Zhang, Chengyun Hu, Xue Li, Shanshan Luo, Chenyu Sun, Iyad Yousef, Yefei Wang, Chaoliang Tang
Format: Article
Language:English
Published: Springer 2025-02-01
Series:Journal of Cancer Research and Clinical Oncology
Subjects:
Online Access:https://doi.org/10.1007/s00432-025-06084-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823863285926068224
author Bilu Li
Yuyan Wu
Yanhong Zhang
Chengyun Hu
Xue Li
Shanshan Luo
Chenyu Sun
Iyad Yousef
Yefei Wang
Chaoliang Tang
author_facet Bilu Li
Yuyan Wu
Yanhong Zhang
Chengyun Hu
Xue Li
Shanshan Luo
Chenyu Sun
Iyad Yousef
Yefei Wang
Chaoliang Tang
author_sort Bilu Li
collection DOAJ
description Abstract Background In recent years, due to various risk factors, the incidence, prevalence, and mortality rates of female lung cancer have been increasing in both China and globally. This has become a significant public health challenge worldwide. Lung cancer not only poses a severe threat to women’s health but also places a heavy burden on families and society. Objective To conduct an in-depth analysis of the trends in disease burden for female lung cancer in China and globally from 1990 to 2021 and to forecast the next 15 years (2022–2037). The aim is to provide a reliable theoretical basis and reference value for clinical research and practice in female lung cancer and offer guidance for resource allocation and policy-making in society. Methods Based on the Global Burden of Disease (GBD) 2021 database, we analyzed the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of lung cancer in China and globally from 1990 to 2021. These metrics were stratified by gender (BOTH, MALE, FEMALE), and the average annual percentage change (AAPC) was calculated for each metric over this period. The JOINPOINT regression model was used to analyze the trends in female lung cancer in China and globally from 1990 to 2021. The ARIMA model was applied to forecast the changes in age-standardized incidence rates (ASIR) and age-standardized mortality rates (ASDR) for the next fifteen years (2022–2037) for female lung cancer in China and globally. Results The results indicate an upward trend in incidence, prevalence, mortality, and DALYs for lung cancer in China. Globally, the prevalence of lung cancer showed an increasing trend, while the incidence, mortality, and DALYs demonstrated a declining trend. Both in China and globally, the incidence, prevalence, mortality, and DALY trends for female lung cancer were higher than those for males. From 1990 to 2021, the incidence, prevalence, mortality, and DALYs of female lung cancer in China exhibited an upward trend, with AAPC growth rates of 1.151%, 2.086%, 0.508%, and 0.210%, respectively. Similarly, globally, the incidence, prevalence, and mortality of female lung cancer also showed an upward trend, with growth rates of 0.576%, 1.123%, and 0.276%, respectively, while DALYs showed a slight decline with an AAPC of -0.029%. Conclusion Although the overall disease burden of female lung cancer is not as high as that of males, the growth rate for female lung cancer is significantly higher than that for males both in China and globally. The overall disease burden and the growth rates of incidence and prevalence of female lung cancer in China are higher than the global average.
format Article
id doaj-art-8b500860c41a4e8b8e74cc71522ac501
institution Kabale University
issn 1432-1335
language English
publishDate 2025-02-01
publisher Springer
record_format Article
series Journal of Cancer Research and Clinical Oncology
spelling doaj-art-8b500860c41a4e8b8e74cc71522ac5012025-02-09T12:10:40ZengSpringerJournal of Cancer Research and Clinical Oncology1432-13352025-02-01151211510.1007/s00432-025-06084-2Global and China trends and forecasts of disease burden for female lung Cancer from 1990 to 2021: a study based on the global burden of disease 2021 databaseBilu Li0Yuyan Wu1Yanhong Zhang2Chengyun Hu3Xue Li4Shanshan Luo5Chenyu Sun6Iyad Yousef7Yefei Wang8Chaoliang Tang9Department of Anesthesiology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaDepartment of Nursing, The First People’s Hospital of HefeiDepartment of Anesthesiology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaDepartment of Anesthesiology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaDepartment of Anesthesiology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaDepartment of Anesthesiology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaInternational Medical Department, The Second Affiliated Hospital of Anhui Medical UniversityDepartment of Physical Education, Birzeit UniversityDepartment of Anesthesiology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaDepartment of Anesthesiology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of ChinaAbstract Background In recent years, due to various risk factors, the incidence, prevalence, and mortality rates of female lung cancer have been increasing in both China and globally. This has become a significant public health challenge worldwide. Lung cancer not only poses a severe threat to women’s health but also places a heavy burden on families and society. Objective To conduct an in-depth analysis of the trends in disease burden for female lung cancer in China and globally from 1990 to 2021 and to forecast the next 15 years (2022–2037). The aim is to provide a reliable theoretical basis and reference value for clinical research and practice in female lung cancer and offer guidance for resource allocation and policy-making in society. Methods Based on the Global Burden of Disease (GBD) 2021 database, we analyzed the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of lung cancer in China and globally from 1990 to 2021. These metrics were stratified by gender (BOTH, MALE, FEMALE), and the average annual percentage change (AAPC) was calculated for each metric over this period. The JOINPOINT regression model was used to analyze the trends in female lung cancer in China and globally from 1990 to 2021. The ARIMA model was applied to forecast the changes in age-standardized incidence rates (ASIR) and age-standardized mortality rates (ASDR) for the next fifteen years (2022–2037) for female lung cancer in China and globally. Results The results indicate an upward trend in incidence, prevalence, mortality, and DALYs for lung cancer in China. Globally, the prevalence of lung cancer showed an increasing trend, while the incidence, mortality, and DALYs demonstrated a declining trend. Both in China and globally, the incidence, prevalence, mortality, and DALY trends for female lung cancer were higher than those for males. From 1990 to 2021, the incidence, prevalence, mortality, and DALYs of female lung cancer in China exhibited an upward trend, with AAPC growth rates of 1.151%, 2.086%, 0.508%, and 0.210%, respectively. Similarly, globally, the incidence, prevalence, and mortality of female lung cancer also showed an upward trend, with growth rates of 0.576%, 1.123%, and 0.276%, respectively, while DALYs showed a slight decline with an AAPC of -0.029%. Conclusion Although the overall disease burden of female lung cancer is not as high as that of males, the growth rate for female lung cancer is significantly higher than that for males both in China and globally. The overall disease burden and the growth rates of incidence and prevalence of female lung cancer in China are higher than the global average.https://doi.org/10.1007/s00432-025-06084-2GBD databaseFemale lung cancerAAPCJOINPOINT regression
spellingShingle Bilu Li
Yuyan Wu
Yanhong Zhang
Chengyun Hu
Xue Li
Shanshan Luo
Chenyu Sun
Iyad Yousef
Yefei Wang
Chaoliang Tang
Global and China trends and forecasts of disease burden for female lung Cancer from 1990 to 2021: a study based on the global burden of disease 2021 database
Journal of Cancer Research and Clinical Oncology
GBD database
Female lung cancer
AAPC
JOINPOINT regression
title Global and China trends and forecasts of disease burden for female lung Cancer from 1990 to 2021: a study based on the global burden of disease 2021 database
title_full Global and China trends and forecasts of disease burden for female lung Cancer from 1990 to 2021: a study based on the global burden of disease 2021 database
title_fullStr Global and China trends and forecasts of disease burden for female lung Cancer from 1990 to 2021: a study based on the global burden of disease 2021 database
title_full_unstemmed Global and China trends and forecasts of disease burden for female lung Cancer from 1990 to 2021: a study based on the global burden of disease 2021 database
title_short Global and China trends and forecasts of disease burden for female lung Cancer from 1990 to 2021: a study based on the global burden of disease 2021 database
title_sort global and china trends and forecasts of disease burden for female lung cancer from 1990 to 2021 a study based on the global burden of disease 2021 database
topic GBD database
Female lung cancer
AAPC
JOINPOINT regression
url https://doi.org/10.1007/s00432-025-06084-2
work_keys_str_mv AT biluli globalandchinatrendsandforecastsofdiseaseburdenforfemalelungcancerfrom1990to2021astudybasedontheglobalburdenofdisease2021database
AT yuyanwu globalandchinatrendsandforecastsofdiseaseburdenforfemalelungcancerfrom1990to2021astudybasedontheglobalburdenofdisease2021database
AT yanhongzhang globalandchinatrendsandforecastsofdiseaseburdenforfemalelungcancerfrom1990to2021astudybasedontheglobalburdenofdisease2021database
AT chengyunhu globalandchinatrendsandforecastsofdiseaseburdenforfemalelungcancerfrom1990to2021astudybasedontheglobalburdenofdisease2021database
AT xueli globalandchinatrendsandforecastsofdiseaseburdenforfemalelungcancerfrom1990to2021astudybasedontheglobalburdenofdisease2021database
AT shanshanluo globalandchinatrendsandforecastsofdiseaseburdenforfemalelungcancerfrom1990to2021astudybasedontheglobalburdenofdisease2021database
AT chenyusun globalandchinatrendsandforecastsofdiseaseburdenforfemalelungcancerfrom1990to2021astudybasedontheglobalburdenofdisease2021database
AT iyadyousef globalandchinatrendsandforecastsofdiseaseburdenforfemalelungcancerfrom1990to2021astudybasedontheglobalburdenofdisease2021database
AT yefeiwang globalandchinatrendsandforecastsofdiseaseburdenforfemalelungcancerfrom1990to2021astudybasedontheglobalburdenofdisease2021database
AT chaoliangtang globalandchinatrendsandforecastsofdiseaseburdenforfemalelungcancerfrom1990to2021astudybasedontheglobalburdenofdisease2021database